-
Je něco špatně v tomto záznamu ?
Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels
Haluzik MM, Lacinova Z, Dolinkova M, Haluzikova D, Housa D, Horinek A, Vernerova Z, Kumstyrova T, Haluzik M.
Jazyk angličtina Země Spojené státy americké
NLK
Free Medical Journals
od 1997 do Před 1 rokem
Open Access Digital Library
od 1997-01-01
- MeSH
- adiponektin genetika krev MeSH
- dieta MeSH
- dietní sacharidy aplikace a dávkování MeSH
- exprese genu účinky léků MeSH
- fenofibrát aplikace a dávkování MeSH
- financování organizované MeSH
- glykemický clamp MeSH
- hmotnostní úbytek účinky léků MeSH
- inzulin farmakologie krev MeSH
- inzulinová rezistence MeSH
- játra chemie účinky léků MeSH
- kosterní svaly chemie MeSH
- krevní glukóza analýza MeSH
- kyseliny mastné neesterifikované analýza MeSH
- lipidy biosyntéza MeSH
- messenger RNA analýza MeSH
- myši inbrední C57BL MeSH
- myši MeSH
- obezita etiologie krev patofyziologie MeSH
- PPAR alfa agonisté fyziologie MeSH
- receptory adiponektinu MeSH
- receptory buněčného povrchu genetika MeSH
- resistin genetika krev MeSH
- triglyceridy krev MeSH
- tuková tkáň chemie patologie MeSH
- velikost orgánu účinky léků MeSH
- ztučnělá játra etiologie farmakoterapie krev MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- myši MeSH
- zvířata MeSH
We studied the effect of peroxisome proliferator-activated receptor-alpha (PPAR-alpha) activation on serum concentrations and tissue expression of resistin, adiponectin, and adiponectin receptor-1 and -2 (AdipoR1 and AdipoR2) mRNA in normal mice and mice with insulin resistance induced by lipogenic, simple-carbohydrate diet (LD). Sixteen weeks of LD feeding induced obesity with liver steatosis and increased insulin levels but did not significantly affect circulating adiponectin or resistin. Treatment with PPAR-alpha agonist fenofibrate decreased body weight and fat pad weight and ameliorated liver steatosis in LD-fed mice with concomitant reduction in blood glucose, free fatty acid, triglyceride, serum insulin levels, and homeostasis model assessment index values. Euglycemic-hyperinsulinemic clamp demonstrated the development of whole-body and liver insulin resistance in LD-fed mice, which were both normalized by fenofibrate. Fenofibrate treatment markedly increased circulating resistin levels on both diets and adiponectin levels in chow-fed mice only. Fat adiponectin mRNA expression was not affected by fenofibrate treatment. Resistin mRNA expression increased in subcutaneous but not gonadal fat after fenofibrate treatment. In addition to fat, a significant amount of adiponectin mRNA was also expressed in the muscle. This expression markedly increased after fenofibrate treatment in chow- but not in LD-fed mice. Adipose tissue expression of AdipoR1 mRNA was significantly reduced in LD-fed mice and increased after fenofibrate treatment. In conclusion, PPAR-alpha activation ameliorated the development of insulin resistance in LD-fed mice despite a major increase in serum resistin levels. This effect could be partially explained by increased AdipoR1 expression in adipose tissue after fenofibrate treatment.
- 000
- 00000naa 2200000 a 4500
- 001
- bmc07523542
- 003
- CZ-PrNML
- 005
- 20111210135730.0
- 008
- 090520s2006 xxu e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Haluzík, Martin, $d 1970- $7 xx0000707
- 245 10
- $a Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels / $c Haluzik MM, Lacinova Z, Dolinkova M, Haluzikova D, Housa D, Horinek A, Vernerova Z, Kumstyrova T, Haluzik M.
- 314 __
- $a Third Department of Medicine, First Faculty of Medicine and General University Hospital, Charles University, 128 08 Prague, Czech Republic. mhalu@lf1.cuni.cz
- 520 9_
- $a We studied the effect of peroxisome proliferator-activated receptor-alpha (PPAR-alpha) activation on serum concentrations and tissue expression of resistin, adiponectin, and adiponectin receptor-1 and -2 (AdipoR1 and AdipoR2) mRNA in normal mice and mice with insulin resistance induced by lipogenic, simple-carbohydrate diet (LD). Sixteen weeks of LD feeding induced obesity with liver steatosis and increased insulin levels but did not significantly affect circulating adiponectin or resistin. Treatment with PPAR-alpha agonist fenofibrate decreased body weight and fat pad weight and ameliorated liver steatosis in LD-fed mice with concomitant reduction in blood glucose, free fatty acid, triglyceride, serum insulin levels, and homeostasis model assessment index values. Euglycemic-hyperinsulinemic clamp demonstrated the development of whole-body and liver insulin resistance in LD-fed mice, which were both normalized by fenofibrate. Fenofibrate treatment markedly increased circulating resistin levels on both diets and adiponectin levels in chow-fed mice only. Fat adiponectin mRNA expression was not affected by fenofibrate treatment. Resistin mRNA expression increased in subcutaneous but not gonadal fat after fenofibrate treatment. In addition to fat, a significant amount of adiponectin mRNA was also expressed in the muscle. This expression markedly increased after fenofibrate treatment in chow- but not in LD-fed mice. Adipose tissue expression of AdipoR1 mRNA was significantly reduced in LD-fed mice and increased after fenofibrate treatment. In conclusion, PPAR-alpha activation ameliorated the development of insulin resistance in LD-fed mice despite a major increase in serum resistin levels. This effect could be partially explained by increased AdipoR1 expression in adipose tissue after fenofibrate treatment.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a adiponektin $x genetika $x krev $7 D052242
- 650 _2
- $a tuková tkáň $x chemie $x patologie $7 D000273
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a krevní glukóza $x analýza $7 D001786
- 650 _2
- $a dieta $7 D004032
- 650 _2
- $a dietní sacharidy $x aplikace a dávkování $7 D004040
- 650 _2
- $a kyseliny mastné neesterifikované $x analýza $7 D005230
- 650 _2
- $a ztučnělá játra $x etiologie $x farmakoterapie $x krev $7 D005234
- 650 _2
- $a exprese genu $x účinky léků $7 D015870
- 650 _2
- $a glykemický clamp $7 D015309
- 650 _2
- $a inzulin $x farmakologie $x krev $7 D007328
- 650 _2
- $a inzulinová rezistence $7 D007333
- 650 _2
- $a lipidy $x biosyntéza $7 D008055
- 650 _2
- $a játra $x chemie $x účinky léků $7 D008099
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a kosterní svaly $x chemie $7 D018482
- 650 _2
- $a obezita $x etiologie $x krev $x patofyziologie $7 D009765
- 650 _2
- $a velikost orgánu $x účinky léků $7 D009929
- 650 _2
- $a PPAR alfa $x agonisté $x fyziologie $7 D047493
- 650 _2
- $a fenofibrát $x aplikace a dávkování $7 D011345
- 650 _2
- $a messenger RNA $x analýza $7 D012333
- 650 _2
- $a receptory adiponektinu $7 D054419
- 650 _2
- $a receptory buněčného povrchu $x genetika $7 D011956
- 650 _2
- $a resistin $x genetika $x krev $7 D052243
- 650 _2
- $a triglyceridy $x krev $7 D014280
- 650 _2
- $a hmotnostní úbytek $x účinky léků $7 D015431
- 700 1_
- $a Lacinová, Zdeňka $7 xx0062138
- 700 1_
- $a Dolinková, Markéta $7 xx0075951
- 700 1_
- $a Haluzíková, Denisa, $d 1970- $7 jo2003163140
- 700 1_
- $a Housa, Daniel, $d 1975- $7 xx0076895
- 700 1_
- $a Hořínek, Aleš, $d 1961- $7 xx0061416
- 700 1_
- $a Vernerová, Zdenka, $d 1960-2020 $7 jo2002104672
- 700 1_
- $a Kumštýřová, T. $7 _BN001103
- 700 1_
- $a Haluzík, Michal $7 xx0063775
- 773 0_
- $w MED00009600 $t Endocrinology $g Roč. 149, č. 9 (2006), s. 4517-4524 $x 0013-7227
- 910 __
- $a ABA008 $b x $y 9
- 990 __
- $a 20090310084605 $b ABA008
- 991 __
- $a 20091004161409 $b ABA008
- 999 __
- $a ok $b bmc $g 655580 $s 508890
- BAS __
- $a 3
- BMC __
- $a 2006 $b 149 $c 9 $d 4517-4524 $i 0013-7227 $m Endocrinology $x MED00009600
- LZP __
- $a 2009-B3/ipme